Paul G. Richardson

TL;DR: Preclinical data showing efficacy of b-AP15 in MM disease models validates targeting DUBs in the ubiquitin proteasomal cascade to overcome proteasome inhibitor resistance and provides the framework for clinical evaluation of USP14/UCHL5 inhibitors to improve patient outcome in MM.

TL;DR: A method to target microbial subpopulations by labeling DNA through stable isotope probing (SIP), followed by WGS sequencing, and extracting a nearly complete genome of a novel methylotroph, Methylotenera mobilis, reconstructing its metabolism and conducting genome-wide analyses is developed.

TL;DR: The preclinical results suggest that MLN8237 may be a promising novel targeted therapy in MM, and combined with dexamethasone, doxorubicin, or bortezomib induces synergistic/additive anti-MM activity in vitro.

TL;DR: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group.

TL;DR: It is demonstrated that checkpoint signaling plays an important role in providing the tumor-promoting, immune-suppressive microenvironment in multiple myeloma, and that PD-1/PD-L1 blockade induces anti–multiple myelomas immune response that can be enhanced by lenalidomide, providing the framework for clinical evaluation of combination therapy.